Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

Annals of Clinical and Translational Neurology

Volumn 2, Issue 1, 2015, Pages 43-55

  Ingwersen, Jens ^a   Menge, Til ^a   Wingerath, Britta ^a   Kaya, Derya ^b   Graf, Jonas ^a   Prozorovski, Tim ^a   Keller, Andreas ^c,d   Backes, Christina ^d   Beier, Markus ^c   Scheffler, Matthias ^c   Dehmel, Thomas ^a   Kieseier, Bernd C ^a   Hartung, Hans Peter ^a   Küry, Patrick ^a   Aktas, Orhan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c The Comprehensive Biomarker Center GmbH   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; MICRORNA 103; MICRORNA 18A; MICRORNA 20B; MICRORNA 29A; MICRORNA 326; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE DELETION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MOUSE; MRNA EXPRESSION ASSAY; MULTIPLE SCLEROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT RESPONSE;

EID: 84930935659     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.152     Document Type: Article

References (56)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;9313:1221-1231.
2. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004;101:14599-14606.
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
4. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005;9:485-495.
5. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;6364:63-66.
6. Baron JL. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;1:57-68.
7. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;9:899-910.
8. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;8:970-979.
9. Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 2012;5:898-905.
10. Aktas O. Natalizumab in clinical practice: managing the risks, enjoying the benefits. J Neurol Neurosurg Psychiatry 2014;85:1181.
11. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007;1:79-95.
12. Theien BE, Vanderlugt CL, Eagar TN, et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2001;8:995-1006.
13. Theien BE, Vanderlugt CL, Nickerson-Nutter C, et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 2003;13:4464-4471.
14. Mittelbrunn M, Molina A, Escribese MM, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci USA 2004;30:11058-11063.
15. Niino M, Bodner C, Simard M, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;5:748-754.
16. Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 2013;16:1400-1408.
17. Lindberg RLP, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194:153-164.
18. Bartel D. MicroRNAs genomics, biogenesis, mechanism, and function. Cell 2004;2:281-297.
19. Baltimore D, Boldin MP, O'Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008;8:839-845.
20. Otaegui D, Baranzini SE, Armañanzas R, et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009;7:e6309.
21. Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009;10:e7440.
22. Lindberg RLP, Hoffmann F, Mehling M, et al. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol 2010;3:888-898.
23. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009;12:1252-1259.
24. Cox MB, Cairns MJ, Gandhi KS, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 2010;8:e12132.
25. de Santis G, Ferracin M, Biondani A, et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol 2010;1-2:165-171.
26. Waschbisch A, Atiya M, Linker RA, et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 2011;9:e24604.
27. Guerau-de-Arellano M, Smith KM, Godlewski J, et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011;12:3578-3589.
28. Gandhi R, Healy B, Gholipour T, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 2013;6:729-740.
29. Fenoglio C, Ridolfi E, Cantoni C, et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler 2013;14:1938-1942.
30. Sondergaard HB, Hesse D, Krakauer M, et al. Differential microRNA expression in blood in multiple sclerosis. Mult Scler 2013;14:1849-1857.
31. Hecker M, Thamilarasan M, Koczan D, et al. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci 2013;8:16087-16110.
32. Keller A, Leidinger P, Steinmeyer F, et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler 2014;3:295-303.
33. Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009;12:3342-3352.
34. Lescher J, Paap F, Schultz V, et al. MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions. J Neuroimmunol 2012;1-2:27-33.
35. Haghikia A, Haghikia A, Hellwig K, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology 2012;22:2166-2170.
36. Vorwerk S, Ganter K, Cheng Y, et al. Microfluidic-based enzymatic on-chip labeling of miRNAs. N Biotechnol 2008;25:142-149.
37. Backes C, Keller A, Kuentzer J, et al. GeneTrail - advanced gene set enrichment analysis. Nucleic Acids Res 2007;35:W186-W192.
38. Chekmenev DS, Haid C, Kel AE. P-Match: transcription factor binding site search by combining patterns and weight matrices. Nucleic Acids Res 2005;33(suppl 2):W432-W437.
39. Betel D, Koppal A, Agius P, et al. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010;8:R90.
40. Huehnchen P, Prozorovski T, Klaissle P, et al. Modulation of adult hippocampal neurogenesis during myelin-directed autoimmune neuroinflammation. Glia 2011;1:132-142.
41. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;5:875-886.
42. Baker D, Amor S. Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. J Neuroimmunol 2012;1-2:78-83.
43. de Kouchkovsky D, Esensten JH, Rosenthal WL, et al. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol 2013;4:1594-1605.
44. Smith KM, Guerau-de-Arellano M, Costinean S, et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 2012;4:1567-1576.
45. Cascio S, D'Andrea A, Ferla R, et al. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010;1:242-249.
46. Lei Z, Li B, Yang Z, et al. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009;10:e7629.
47. Zhu E, Wang X, Zheng B, et al. miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3. J Immunol 2014;192:5599-5609.
48. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;7359:214-219.
49. Koch MW, Metz LM, Kovalchuk O. Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol 2013;1:35-43.
50. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;7068:685-689.
51. Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol 2012;1:70-79.
52. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;2:217-222.
53. Argaw AT, Gurfein BT, Zhang Y, et al. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 2009;6:1977-1982.
54. Harris TJ, Grosso JF, Yen H, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007;7:4313-4317.
55. Nguyen K, Sylvain NR, Bunnell SC. T cell costimulation via the integrin VLA-4 inhibits the actin-dependent centralization of signaling microclusters containing the adaptor SLP-76. Immunity 2008;6:810-821.
56. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 2005;11:565-571.